New MMR vaccine shows promise in protecting infants
NCT ID NCT06399003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new measles, mumps, and rubella (MMR) vaccine made by Shanghai Institute of Biological Products in 1,200 healthy children aged 9-11 months. The goal was to see if it works as well as the licensed GSK MMR vaccine and is safe. Children received one dose, and researchers checked their immune response and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEASLES-MUMPS-RUBELLA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Victoria Biomedical Research Institute(VIBRI)
Kisumu, Kenya